Tesla sold 68,280 China-made vehicles in October, a 5.3% drop from the previous year, with Model 3 and Model Y deliveries down 22.7% month-over-month. Tesla extended its interest-free financing for ...

A new guideline advises most patients to continue GLP-1 drugs before surgery. The FDA warns against California-made ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

Scemblix was granted accelerated approval by the FDA for the treatment of certain patients newly diagnosed with chronic ...

The new accelerated approval covers the use of Scemblix for newly diagnosed patients with Philadelphia chromosome-positive ...

Vas Narasimhan, CEO at Novartis, discusses third-quarter results, and explains the strategy behind development of the company's most in-demand treatments.

While Novartis provided an optimistic take on 2024, the lack of commentary on 2025 “may disappoint,” Bloomberg Intelligence ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an ...

Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...